GLP1R and diabetes mellitus: For instance, a meta-analysis of seven studies discovered that GLP-1 RA, compared to a placebo, decreases the risk of all-cause mortality in adults with diabetes and cardiovascular disease.22 Except for the investigational oral Semaglutide, the formulations are currently administered as subcutaneous injections at different dosing intervals.